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Abstract
The large GTPase dynamin 2 is a key player in membrane and cytoskeletal dynamics mutated in centronuclear myopathy
(CNM) and Charcot-Marie Tooth (CMT) neuropathy, two discrete dominant neuromuscular disorders affecting skeletal
muscle and peripheral nerves respectively. The molecular basis for the tissue-specific phenotypes observed and the
physiopathological mechanisms linked to dynamin 2 mutations are not well established. In this study, we have analyzed the
impact of CNM and CMT implicated dynamin 2 mutants using ectopic expression of four CNM and two CMT mutations, and
patient fibroblasts harboring two dynamin 2 CNM mutations in established cellular processes of dynamin 2 action. Wild type
and CMT mutants were seen in association with microtubules whereas CNM mutants lacked microtubules association and
did not disrupt interphase microtubules dynamics. Most dynamin 2 mutants partially decreased clathrin-mediated
endocytosis when ectopically expressed in cultured cells; however, experiments in patient fibroblasts suggested that
endocytosis is overall not defective. Furthermore, CNM mutants were seen in association with enlarged clathrin stained
structures whereas the CMT mutant constructs were associated with clathrin structures that appeared clustered, similar to
the structures observed in Dnm1 and Dnm2 double knock-out cells. Other roles of dynamin 2 including its interaction with
BIN1 (amphiphysin 2), and its function in Golgi maintenance and centrosome cohesion were not significantly altered. Taken
together, these mild functional defects are suggestive of differences between CMT and CNM disease-causing dynamin 2
mutants and suggest that a slight impairment in clathrin-mediated pathways may accumulate over time to foster the
respective human diseases.
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Introduction
Dynamins are large GTPases implicated in a variety of cellular
processes including membrane and cytoskeletal dynamics as well
as mitotic events. Classical dynamins were originally identified as
microtubule interacting proteins [1] although their direct role in
microtubule dynamics remains controversial [2,3]. They are
composed of a GTPase domain, a middle domain, a GTPase
Effector Domain (GED), a Pleckstrin Homology domain (PH), and
a Proline/arginine Rich Domain (PRD) that binds a plethora of
proteins containing SH3 (Src homology 3) domains [4,5].
Although the three classical dynamins (dynamins 1, 2 and 3)
share high sequence identity they have different expression profiles
and may have discrete roles. Dynamin 2 (DNM2) is ubiquitously
expressed whereas dynamin 1 is predominantly expressed in brain
and dynamin 3 has been detected in brain, testis and lung
[6,7,8,9,10]. In humans, although we lack a complete expression
profile for dynamin 2, it is expressed at least in skeletal muscle and
peripheral nerve [11].
To date, only dynamin 2 has been implicated in disease out of
the classical dynamins. DNM2 mutations have been linked to two
autosomal dominant diseases: centronuclear myopathy (CNM)
and the axonal or intermediate form of dominant Charcot-Marie-
Tooth (CMT) disease [12,13,14]. Most missense mutations linked
to CMT are located within the PH domain while CNM with
either adult or early onset has been linked to mutations in the
middle and the PH domains, respectively [11,15,16,17,18]. The
middle domain of dynamin 2 has been ascribed a role in
centrosome cohesion [19] and seems to be important for dynamin
oligomerization [20]. It has also been proposed to contribute to
conformational changes induced by stimulation of GTP hydrolysis
[21]. The PH domain is involved in phosphoinositide binding with
a higher affinity for PtdIns(4,5)P2 [22]. Although several CNM
and CMT-causing mutations have been identified in close
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lead to distinct pathologies affecting discrete tissues remains an
intriguing question. A possible concomitant expression of muscle
weakness and nerve involvement was suggested in some patients
although, in most cases, DNM2 mutations have clear non-
overlapping clinical outputs [23,24]. Recently, it was shown that
CNM mutations found within the PH domain increase the
stability of the assembled form of dynamin but do not affect their
lipid binding properties [25]. In contrast, tested CMT mutants
displayed decreased oligomer stability [25]. Furthermore, middle
domain CNM mutants were demonstrated to form more stable
higher order polymers and displayed increased basal GTPase
activity [26]. Therefore, it seems that CNM and CMT mutations
affect dynamin 29s biochemical properties in discrete ways.
However, their effect on known cellular functions of dynamin 2
has not been addressed.
In this study, we set out to investigate the impact and differences
between CNM and CMT mutations using ectopic expression and
patient fibroblasts in established cellular processes of dynamin 2
action. Our observations suggest that CMT mutants maintain an
interaction with MTs whilst CNM mutants lose this property. In
addition, CNM mutant ectopic proteins are seen in association
with enlarged clathrin-positive punctae. Although, an effect on
clathrin-mediated endocytosis is apparent for all tested mutations
after ectopic expression, albeit to different extents, experiments in
patient fibroblasts suggest that this pathway is not largely affected
in the related diseases.
Results
Differential impact of mutations on the subcellular
localization of dynamin 2
In order to address the cellular impact of dynamin 2 mutations
implicated in centronuclear myopathy and Charcot-Marie Tooth
disease, we engineered constructs harboring patient mutations
located within the middle and PH domain of dynamin 2 (Fig. 1A).
Figure 1. Localization profile of dynamin 2 CNM and CMT mutants. (A) Schematic representation of the dynamin 2 protein with protein
domains depicted; GTPase, middle domain, PH: pleckstrin homology domain, GED: GTPase Effector Domain, PRD: proline-rich domain. Position of
dynamin 2 mutations implicated in Charcot-Marie Tooth disease (CMT, above) and centronuclear myopathy (CNM, below) employed in this study are
indicated. (B) Enrichment of dynamin 2 associated with vesicular structures. COS-1 cells transiently transfected with indicated dynamin 2 mutants
were treated with 0.5% (v/v) Triton X-100, 2% (v/v) paraformaldehyde for 2 min at 37uC followed by fixation in paraformaldehyde and processing
with anti-MYC specific antibodies. The subcellular localization profile for the wild type (WT) and indicated mutants is depicted. Clustered structures
(arrowheads) and enlarged puncta (arrows) are indicated. (C) Enrichment of dynamin 2 along cytoskeletal elements. COS-1 cells transiently
transfected with indicated dynamin 2 constructs were treated with Brinkley buffer containing 1% (v/v) Triton X-100 for 10 min at 37uC, to preserve
cytoskeletal structures, followed by fixation in paraformaldehyde, and processed with anti-dynamin 2 specific antibodies. Wild type (WT) and CMT
mutants display a filamentous profile not seen for CNM mutants.
doi:10.1371/journal.pone.0027498.g001
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PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27498As patients with dynamin 2-related diseases are heterozygous for
the mutations, we chose to express these constructs in cells
containing endogenous levels of wild type dynamin 2. COS-1 cells
were transiently transfected with these constructs and were
subjected to distinct treatments to compare the localization profile
of both wild type (WT) and mutant dynamin 2 constructs. To
remove cytosolic dynamin 2, the cells were treated with 0.5% (v/v)
Triton X-100, 2% (v/v) paraformaldehyde ([27]; vesicular
enrichment fixation). As can be seen in Fig. 1B, wild-type
dynamin 2 localised to puncta throughout the cell and at the
perinuclear region, potentially at the endosomal compartment and
the Golgi network [6,28,29]. The staining profile for mutated
dynamin 2 constructs was comparable, although the dynamin 2
vesicular structures appeared somewhat enlarged in cells express-
ing CNM mutants.
As ectopic dynamin 2 has been previously reported to associate
with interphase microtubules (MTs), we treated cells expressing
wild type or mutated dynamin 2 proteins with 1% (v/v) Triton X-
100 in Brinkley buffer prior to fixation ([2,3]; cytoskeletal
enrichment fixation). This allows for preservation of the
cytoskeleton and in particular of MTs, whilst it results in removal
of cytosolic proteins. Under these conditions, wild type and CMT
mutants dynamin 2 constructs formed a filamentous pattern,
whereas the four dynamin 2 constructs harboring CNM mutations
showed a punctate pattern throughout the cytoplasm (Fig. 1C),
similar to the structures observed in Fig. 1B. As the filamentous
pattern observed was reminiscent of MTs we co-stained for
dynamin 2 and b tubulin under the same conditions and found
that wild type and CMT mutants partially co-localized with MTs,
while this co-localization was clearly decreased for dynamin 2
constructs harboring CNM mutations (Fig. 2 and Fig. S1). We
were intrigued by this observation as a dynamin 2 construct with
the CMT-associated 551D3 variation has been previously shown
to display increased MT association [3]. Our observations
suggested that, conversely, dynamin 2 CNM mutations may result
in reduced dynamin 2 association with interphase MTs. The
punctate pattern observed in the case of CNM mutants was
examined further however we could not identify their nature.
They did not co-label with EEA1, clathrin light chain, or
proteasomal markers (data not shown). To explore the decreased
MT association observed for dynamin 2 CNM mutants (see Fig. 2),
we assessed MT morphology and dynamics in fibroblasts obtained
from CNM patients harboring the R465W and S619L mutation,
point mutations in the middle and PH domain of dynamin 2
respectively. These fibroblasts thus contain both wild-type and
mutated alleles and express similar levels of dynamin 2 protein
compared to control fibroblast lines as shown by western blot
analysis (Fig. 3B). The MTs appeared normal for both patient lines
as revealed by staining with b tubulin specific antibodies (Fig. 3A;
left panels). Treatment of fibroblasts with nocodazole, an MT-
depolymerizing drug, resulted in complete loss of MTs, with MT
nucleation and elongation occurring similarly following drug
removal for control and patient cells (Fig. 3A). Dynamin 2 was
reported to affect the dynamic nature of MTs, as targeted
disruption of Dnm2 and Dnm1 in mouse embryonic cells lead to an
increased level of acetylated tubulin, a sub-population of stabilized
a tubulin [30]. However, we observed no differences between
control and patient fibroblasts by immunofluorescence (Fig. 3A;
far right panels). No differences in the levels of acetylated tubulin
were observed when these patient fibroblasts were compared to
three control fibroblast lines by western blot analysis employing
anti-acetylated tubulin antibodies and several control antibodies
(Fig. 3B). Taken together, these observations indicate a differential
impact of CMT and CNM mutations on the subcellular
localization of dynamin 2, while they do not readily affect
interphase MT dynamics.
Impact of dynamin 2 mutations on clathrin-mediated
endocytosis
Dynamin has an established role in clathrin-mediated endocy-
tosis (CME) [31]. To investigate the effect of disease-related
dynamin 2 mutants on this process, we monitored CME in cells
transfected with the various mutants following incubation with
fluorescently labeled transferrin. As shown in Fig. 4 and Fig. S2,
we observed a significant decrease in transferrin uptake for all the
mutants tested except for the G358R mutation that is related to a
CMT phenotype. This decrease was more pronounced for the
K562E CMT mutation (decrease by approximately 50% com-
pared to wild type dynamin 2).
We next tested whether ectopic expression of CNM and CMT
dynamin 2 mutant constructs can reveal subtle effects on the
morphology of clathrin positive structures. Co-staining of cells
overexpressing the various mutants with anti-dynamin 2 and
clathrin light chain (CLC) antibodies revealed differences for the
two classes of mutants. CMT mutants were seen in association
with clustered punctae whereas CNM mutants were seen in
association with enlarged clathrin positive structures (Fig. 5 and
Fig. S3). The clustered structures observed in the case of the
K562E expressing cells were reminiscent to the clustering of
clathrin coated vesicles observed in conditional mouse embryonic
fibroblasts lacking Dnm1 and Dnm2 expression (Fig. S3) and as
previously reported [30]. On the other hand, the appearance of
enlarged structures co-labeled for both dynamin 2 and clathrin in
cells overexpressing CNM mutants would be consistent with
increased fusion events or a decrease in fission events.
To investigate whether these observations reflect an impact on
dynamin’s role in CME, we investigated this process in patient
fibroblasts with the R465W or S619L CNM mutations by
measuring the levels of internalized fluorescently labeled transfer-
rin following serum deprivation. While dynasore or incubation at
+4uC substantially decreased transferrin uptake; untreated control
and patient fibroblasts displayed similar levels of transferrin
internalization (Fig. 6A). As endogenous dynamin 2 protein levels
were comparable for patient and control fibroblasts employed in
our study (see Fig. 3B), we envisaged that a potential upregulation
of dynamin 1 could make up for and hence mask an impact on
endocytosis in the patient fibroblasts assessed. Dynamin 1 has been
shown to be upregulated in fibroblasts lacking dynamin 2 [30] and
can compensate to some extent for dynamin 29s role in
endocytosis. The protein levels of dynamin 1, albeit low in
fibroblasts, were similar for all the cell lines analyzed (Fig. 6B)
suggesting that dynamin 1 is not upregulated in the R465W and
S619L fibroblast lines and thus could not differentially influence
CME. In addition, dynamin 2 was found in association with
clathrin coated vesicles similarly in control and patient fibroblasts,
following fixation with 0.5% (v/v) Triton X-100, 2% (v/v)
paraformaldehyde, suggesting that dynamin’s role in endocytosis
is not altered in patient cells (Fig. 6C).
Dynamin 2 recruitment to BIN1-induced membrane
tubules
BIN1 (amphiphysin 2), a dynamin 2-interacting partner with an
established role in clatrhin-mediated endocytosis, has been found
mutated in recessive forms of CNM [32]. In particular, a disease-
causing BIN1 mutation was reported to strongly decrease BIN1
binding to dynamin 2, suggesting that a disruption of the BIN1-
dynamin 2 complex may play a role in the CNM pathology [32].
Cellular Impact of Dynamin 2 Mutations
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interfere with dynamin 2-BIN1 interactions, we performed pull-
down assays employing lysates from COS-1 cells transfected with
CNM or CMT dynamin 2 mutant constructs that were combined
to recombinant GST-SH3 (BIN1) or GST proteins coupled to
glutathione beads. All dynamin 2 mutants were pulled-down
efficiently with the SH3 domain of BIN1, suggesting that the
mutations do not impact on this interaction at least under the
conditions implemented (Fig. 7A). These results are consistent with
the fact that the main BIN1-binding site on dynamin 2 is the
Proline-rich domain [33,34]. As BIN1 induces the formation of
tubules when over-expressed in COS-1 cells [32] we next assessed
whether mutations in dynamin 2 disrupt its recruitment to BIN1-
induced membrane tubules. Wild type dynamin 2 localized to
Figure 2. CNM mutations impact on dynamin 29s localization to microtubules. COS-1 cells transiently transfected with the indicated
constructs were treated with Brinkley buffer and 1% (v/v) Triton X-100, followed by fixation in paraformaldehyde and staining with anti-dynamin 2
and anti-b tubulin specific antibodies. The CMT mutants (G358R, K562E) display MT association, unlike dynamin 2 CNM (R465W, S619L) and K44A
mutants that are seen decorating punctate structures.
doi:10.1371/journal.pone.0027498.g002
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PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27498Figure 3. MT dynamics in CNM patient fibroblasts. (A) MT dynamics in fibroblasts from control and CNM patients harboring the R465W or
S619L mutation. Fibroblasts were left untreated or were treated with 5 mM nocodazole for 2 h at 37uC. To allow for partial recovery of MTs,
nocodazole was removed and cells were placed at 37uC for 5 min. To view MTs, the cells were stained with b tubulin specific antibodies. Stabilized
MTs were visualized with acetylated tubulin-specific antibodies. (B) Levels of acetylated tubulin are comparable for control and patient fibroblast
lines. Equal amounts of indicated fibroblast lysates were subjected to SDS-PAGE and were analyzed by western blot employing anti-acetylated
tubulin antibodies and controls (anti-EEA1, anti-dynamin 2 and anti-GAPDH).
doi:10.1371/journal.pone.0027498.g003
Figure 4. Effect of dynamin mutants’ overexpression on transferrin uptake. COS-1 cells expressing ectopic wild type and mutant dynamin 2
constructs were incubated with fluorescently labeled transferrin for 15 min and were subsequently fixed and processed with anti-MYC antibodies for
microscopic observation. Quantification of transferrin uptake employing the Metamorph software allowed for calculation of the ratio of the intensity
of transfected cells/untransfected cells representing the correlation of three independent experiments. The student’s t test was used for statistical
analysis of three independent experiments, * P,0.01, ** P,0.05, *** P.0.05.
doi:10.1371/journal.pone.0027498.g004
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dynamin 2 mutants tested were also seen in association with
tubules decorated with BIN1 confirming our pull-down findings.
BIN1-induced tubules persisted following recruitment of ectopic
dynamin 2 under these conditions (Fig. 7B and Fig. S4).
Dynamin 2 mutants do not affect centrosome cohesion
or Golgi maintenance
To investigate if other known functions of dynamin 2 are affected
by the CMT and CNM mutations, we monitored its role in Golgi
network maintenance [3,28,35,36] and centrosome cohesion
[13,19]. Overexpression of the mutants in COS-1 did not affect
Golgi morphology as revealed by staining with anti-golgin 97
antibodies (Fig. 8A and data not shown). No effect on Golgi
morphology was evident in CNM fibroblasts (R465W and S619L)
either (Fig. 8B). Overexpression of wild type or mutated dynamin 2
constructs in COS-1 cells did not affect centrosome positioning
(Fig. 9A and data not shown). In addition, we did not observe any
differences in the organization of centrioles in the R465W or S619L
patient fibroblasts when compared to control fibroblasts by staining
for c tubulin following methanol:acetone fixation (Fig. 9B), and as
previously reported for the R465W mutation [13]. These
observations suggest that the dynamin 2 mutations tested do not
readily affect Golgi maintenance or centrosome positioning.
Figure 5. Comparison of dynamin 2 mutants’ localization to clathrin-positive structures following a vesicular enrichment fixation.
COS-1 cells transiently transfected with indicated dynamin 2 mutants were treated with 0.5% (v/v) Triton X-100, 2% (v/v) paraformaldehyde for 2 min
at 37uC followed by fixation in paraformaldehyde and processing with anti-MYC specific antibodies and anti-clathrin light chain (CLC) antibodies.
Samples were analyzed by confocal microscopy. A mask for the colocalization that was created employing the Fiji software is shown (right panels).
Note the presence of aggregated vesicles in dynamin 2 G358R and K562E-expressing cells (arrowheads) and the presence of enlarged clathrin-
positive punctae (arrows) in the case of R465W and S619L mutant expressing cells.
doi:10.1371/journal.pone.0027498.g005
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Although dynamin 2 mutations lead to two discrete pathologies
affecting different tissues, the molecular basis of this specificity is
not understood. It seems that, for example, dynamin 2 mutations
in the middle and PH domains leading to CNM increase its
GTPase activity through potentially the stabilization of higher
order polymers [25,26]. Conversely, the K562E CMT mutation
displays decreased GTPase activity [25]. It is not unreasonable to
think that changes in the properties and assembly-state of dynamin
2 observed in in vitro assays may be relevant to the effect of these
mutations at the cellular level. In this study, we have analyzed the
impact of both CNM and CMT-causing mutations on character-
ized cellular pathways of dynamin 2 action. We tested the impact
of these mutant proteins in the presence of endogenous wild type
dynamin 2, both in the ectopic expression studies and at the
endogenous level in patient fibroblasts, to be closer to the
physiological conditions observed in the associated pathologies as
patients are heterozygous for the mutations. We did not observe
any effect on Golgi maintenance and centrosome cohesion, two
reported dynamin 2 functions [19,37], suggesting that other
functions are affected in the linked diseases.
Although we observed a clear loss of MT association in the case
of CNM mutant proteins, we could not detect a direct impact on
MT dynamics in patient cells. An increase in acetylated tubulin (a
sub-population of stable MTs) has been previously reported in
Dnm2 knockout mouse embryonic fibroblasts [30], in HeLa cells
expressing DNM2 targeting siRNA [3], in flies expressing the shibire
temperature sensitive mutant of dynamin [38], and in cells
overexpressing the 551D3 CMT mutant [3]. However, consistent
Figure 6. CNM mutations do not impact on transferrin uptake in patient fibroblasts harboring the R465W or S619L mutation. (A)
Quantification of transferrin uptake. Control and patient fibroblasts were serum-starved and incubated with fluorescently labeled human transferrin
for 15 min at 37uC. Levels of internalized transferrin were analysed by FACS following removal of non-internalized transferrin. Error bars represent
standard deviation for three independent expreriments. The student’s t test was used for statistical analysis of three independent experiments,
P,0.05 were considered significant. (B) Levels of dynamin 1 in control and patient fibroblasts. Equal amounts of control and patient (R465W and
S619L) fibroblasts were analyzed by western blot employing anti-dynamin 1 and indicated control antibodies. (C) Endogenous dynamin 2 co-
localizes with clathrin light chain (CLC). Control and patient fibroblasts (R465W and S691L) were fixed in 0.5% (v/v) Triton X-100, 2% (v/v)
paraformaldehyde. Right panels depict masks corresponding to the co-localization of anti-dynamin 2 and anti-CLC that were generated employing
the Fiji program.
doi:10.1371/journal.pone.0027498.g006
Cellular Impact of Dynamin 2 Mutations
PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27498with our observations, Tanabe and Takei did not observe an effect
on acetylated tubulin when they expressed the K562E CNM
mutant [3]. Thus, defects in MT dynamics appear to be linked
either to loss of the dynamin 2 protein or the deletion of the PRD
domain [2,30]. The 551D3 CMT mutant could still bind to MTs
and exert a potential dominant negative effect thus resulting in
increased MT stability however, we did not observe an effect on
MT dynamics in the patient fibroblasts assessed. The presence of a
Figure 7. CNM and CMT dynamin 2 mutations do not impact on BIN1 (amphiphysin 2) interaction. (A) CNM and CMT mutants interact
with the BIN1 SH3 domain. Lysates from COS-1 cells transiently transfected with constructs encoding indicated dynamin 2 mutants were subjected to
pull-down assays employing recombinant GST-SH3 (BIN1) or GST alone coupled to glutathione beads. The samples were analyzed by SDS-PAGE and
were subjected to western blot analysis employing anti-MYC specific antibodies. The input fraction represents 5% of total material employed in the
pull-downs. Below, Coomassie Blue staining showing recombinant proteins coupled to beads employed for pull-downs. (B) Recruitment of dynamin
2 constructs to BIN1-induced membrane tubules. COS-1 cells were transiently transfected with vectors encoding indicated dynamin 2 constructs and
the GFP-BIN1 chimera. Cells were fixed in paraformaldehyde followed by staining with anti-MYC specific antibodies. Both CNM and CMT dynamin 2
mutants can be seen in association with BIN1 tubules.
doi:10.1371/journal.pone.0027498.g007
Cellular Impact of Dynamin 2 Mutations
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27498normal copy of dynamin 2 in the patient cells is probably sufficient
to sustain normal MT dynamics. However, we cannot exclude that
an effect on MT stabilization and dynamics could become
apparent in muscle cells during myotube formation as MT
dynamics have been implicated in muscle cell differentiation
[39,40]. Alternatively, the dynamin 2 CNM mutations tested here
may not impact on MT dynamics but on other dynamin 2 related
pathways, as suggested by our results.
An impact on CME has been reported previously for both
CNM and CMT dynamin 2 mutations [3,11,14]. We confirmed a
partial inhibition of CME in COS-1 cells overexpressing CMT
and CNM mutants by approximately 30% to 50% (see Fig. 4),
except for the G358R CMT mutant for which the decrease in
transferrin uptake was not significant. However, an effect on CME
was not evident in patient fibroblasts harboring the R465W or the
S619L CNM-related mutations. Interestingly, Bitoun and col-
leagues noted a decrease in CME in a cell line with the R465W
CNM mutation after 5 minutes of uptake [11]; taken together with
our results it suggests that dynamin 2 mutations delay but do not
block endocytosis, at least in the case of this mutation. The
apparent discrepancy in the transferrin uptake rate between the
patient fibroblasts and the overexpression of the equivalent mutant
constructs suggests that the relative abundance of the mutant
protein compared to wild type dynamin 2 protein potentially
influences the ability of dynamin 2 to readily participate in CME.
In the case of the overexpression in COS-1 cells we probably have
an excess of ectopically expressed dynamin 2 compared to
endogenous protein suggesting that either a high level of mutant
or an accumulation of the mutated protein over time in patients
may cause partial CME defects. It can also reflect an accumulation
of a minor cellular defect over time in the affected tissue. This is
supported by the surprising lethality of the dynamin 2 (R465W)
homozygous knock-in and the CME defect observed in homozy-
gous knock-in MEFs that was absent from heterozygous knock-in
MEFs [41]. It is noteworthy however, that the clathrin-positive
structures observed following overexpression of the two different
classes of mutant dynamin 2 proteins were distinct (see Fig. 5).
CNM-related dynamin 2 mutants were seen in association with
enlarged clathrin-positive structures. Taken together with our
previous observations on the mis-localization of these mutants (see
Fig. 2 and Table 1), it suggests that CNM mutations reduce
dynamin 29s ability to associate with MTs by either affecting their
ability to bind to MTs or by decreasing their availability for
binding to MTs due to increased association with clathrin-positive
Figure 8. Effect of dynamin 2 mutations on Golgi network morphology. (A) Overexpression of CNM and CMT dynamin 2 mutants does not
impact on Golgi morphology. COS-1 cells expressing ectopic dynamin 2 constructs were fixed in paraformaldehyde and were stained with anti-
dynamin 2 and anti-golgin 97 antibodies. (B) Golgi network morphology is comparable between control and patient fibroblasts harboring CNM
mutations. Fibroblasts were fixed in paraformaldehyde and were stained with anti-GM130 antibodies and Hoechst.
doi:10.1371/journal.pone.0027498.g008
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formation of clustered structures reminiscent to the arrested pits
observed in dynamin knockout cells [30]. Potentially this is linked
to the decreased GTPase activity reported for the K562E mutant
in the presence of liposomes [25], which may render the protein
less efficient at exerting its function during clathrin coated vesicle
maturation. In addition, the co-localization of the dynamin
mutants to clathrin positive structures and the recruitment of all
dynamin mutants to BIN1-induced tubules suggest that it is not a
defect in dynamin’s recruitment to clathrin coated pits per se but
most likely a downstream event. Furthermore, while some
amphiphysin 2 mutations leading to CNM disrupt the binding
and recruitment of dynamin 2 to BIN1-induced membrane
tubules [32], we show here that the dynamin 2 mutations tested
do not have a similar impact. This is important for a better
understanding of the pathophysiology of such diseases and suggests
that dynamin 2 is downstream of amphiphysin 2 in this pathway.
Given the relative mild phenotype associated with the so far
identified dynamin 2 mutations leading to disease, compared to the
embryonic lethality of the dynamin 2-null mouse between
embryonic days 8 and 12 [30], it is not surprising that they seem
to lead to a partial disruption of dynamin’s function. These
observations are supported by the recent study characterizing the
first Dnm2 knock-in mouse model [41]. Although the heterozygous
R465W knock-in mouse is viable and recapitulates features of
CNM, the homozygous knock-in is perinatal lethal [41]. This
suggests that the wild type protein can rescue most of the effect of
the mutated allele. Ectopicexpression of this CNMmutation inwild
type mice with an adeno-associated viral vector (AAV) supported a
dominant effect of the mutation on muscle fiber structural
maintenance. Importantly, only skeletal muscles were transduced
inthismodel[42].AsmusclesfromtheR465WKImouse,whereall
tissues express the mutated protein, displayed very similar defects to
the AAV model, it points to a muscle-specific impact of the CNM
mutations.Animal modelsfor the CMTdisease linkedto dynamin2
mutations are not yetavailable and will be very valuable to decipher
dynamin 2 pathways implicated in disease and their tissue-specific
pathological mechanisms.
Materials and Methods
Cloning and constructs
The generation of the wild-type human dynamin 2 (isoform 1;
Accession number NM_001005360) pENTR1A construct and the
Figure 9. Effect of dynamin 2 mutations on centrosome cohesion. (A) Overexpression of CNM and CMT dynamin 2 mutants does not impact
on centrosome cohesion. COS-1 cells expressing ectopic dynamin 2 constructs were fixed in methanol:acetone and were stained with anti-dynamin 2
and anti-c tubulin antibodies. (B) Centrosome position is comparable between control and patient fibroblasts harboring CNM mutations. Control and
patient fibroblasts harboring CNM mutations were fixed in methanol:acetone and were stained with anti-c tubulin antibodies and Hoechst.
doi:10.1371/journal.pone.0027498.g009
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elsewhere [32]. Human dynamin 2 CMT (G358R and K562E),
CNM (R465W, S619L, R522H and P627H) and the artificial
(K44A) mutant constructs were generated by primer directed PCR
mutagenesis. Mammalian expression C-terminal myc-His tagged
constructs were generated by recombination employing the
GatewayH system (Invitrogen). The construction of pEGFP-C1-
BIN1 and pGEX2T-SH3 (BIN1) has been previously described
[32]. All constructs were verified by direct sequencing.
Cell culture
Control and patient (R465W and S619L mutations) fibroblasts
were grown in Dulbecco’s modified medium (DMEM) supple-
mented with 10% (v/v) fetal calf serum (FCS) at 37uCi na
humidified incubator, 5% CO2. Conditional Dnm1 and Dnm2
double knock-out fibroblasts, a kind gift from S. Ferguson and P.
De Camilli, were grown in DMEM supplemented with 10% FCS
in a humidified incubator supplemented with 5% CO2 at 37uC
[30]. Deletion of Dnm1 and Dnm2 was induced by treatment with
4-hydroxytamoxifen (Sigma Aldrich) as specified by Ferguson et al.
(2009). COS-1 cells were grown in DMEM supplemented with 5%
(v/v) FCS under the same conditions and were transiently
transfected with expression plasmids using LipofectAmine 2000
according to manufacturer’s instructions (Invitrogen). Equal
amounts of protein for control and patient fibroblasts were
resuspended in Laemnli loading dye and analyzed by Tris-Glycine
SDS-PAGE and western blot analysis. Antibodies employed
included anti-GAPDH (Millipore), anti-acetylated tubulin (Sigma
Aldrich), anti-dynamin 1 (Epitomics), anti-dynamin 2 (R2680;
IGBMC [42]) and anti-b tubulin (clone 1TUB2A; IGBMC).
Immunofluorescence assays
Cells were seeded directly onto sterilized coverslips. For c
tubulin staining, cells were fixed in cold methanol:acetone for
20 min at 220uC. For dynamin localization to MTs, cells were
incubated in Brinkley buffer (80 mM PIPES pH 7.5, 1 mM
MgCl2, 4% (w/v) polyethylene glycol, 1% (v/v) Triton X-100) for
10 min at 37uC followed by fixation in paraformaldehyde as
described in [3]. For removal of cytosolic proteins, cells were fixed
in 0.5% (v/v) Triton X-100, 2% (v/v) paraformaldehyde (EMS)
for 2 min as specified in [27]. BIN1-induced tubules were
preserved by fixing COS-1 cells in 2% paraformaldehyde (v/v)
for 1 h at room temperature. For nocodazole treatment,
fibroblasts were left untreated or were treated with 5 mM
nocodazole (Sigma Aldrich) for 2 h at 37uC. For microtubules
network recovery experiments, the drug was removed, cells were
rinsed in pre-warmed cultured media and microtubules were
allowed to recover for 5 min at 37uC. Antibodies employed in
immunofluorescence assays included anti-golgin 97 (Invitrogen),
anti-GM130 (BD Biosciences), anti-c tubulin (Santa Cruz
Biotech), anti-acetylated tubulin (Sigma Aldrich), anti-clathrin
light chain (Sigma Aldrich), anti-EEA1 (Abcam), anti-b tubulin
(clone 1TUB2A; IGBMC) and anti-dynamin 2 antibodies (R2641;
IGBMC). These antibodies were revealed by employing anti-
rabbit AlexaFluor 488 conjugated or anti-mouse AlexaFluor 594
conjugated secondary antibodies (Invitrogen). Nuclei were stained
with Hoechst 33528 (Sigma Aldrich) and samples were mounted in
FluorSave
TM reagent (Calbiochem).
FACS analysis of transferrin uptake in fibroblasts
Serum-deprived fibroblasts were pulsed with AlexaFluor 633
conjugated transferrin (Invitrogen) for 15 min. Cells were washed
twice for 3 min in 0.2 M acetic acid, 0.5 M NaCl followed by
washing in 0.25 M Tris (pH 10) for 2 min and were subsequently
fixed in 1% (v/v) formaldehyde. To block dynamin action, cells were
treated with dynasore (Sigma Aldrich) as described by Macia et al.
(2006) [43]. The samples were analyzed on the FACSCalibur (BD
Biosciences) employing the Cell Quest Pro program (BD Biosciences).
Subsequent analysis was performed employing the Flowjo software
(Tree Star Inc., Oregon, USA). The student’s t test was used for
statistical analysis. P values of ,0.01 were considered significant. To
calculate the % of transferrin uptake, the fluorescence of the control
w i t ht h eh i g h e s tu p t a k ew a sn o t e da s1 0 0 % .T h e%o fu p t a k ef o ra l l
other cell lines was calculated as a ratio against the control cells.
Transferrin uptake in transfected COS-1 cells
COS-1 cells transiently transfected with dynamin 2 wild type or
mutant constructs were serum-starved for 1 h prior to treatment
with AlexaFluor 488 conjugated transferrin for 15 min at 16 h
post-transfection. Cells were fixed, permeabilized and processed
with anti-MYC antibodies. Images were acquired using a
DMRXA2 microscope (Leica Microsystems Gmbh). Quantifica-
tion was performed employing the Metamorph software (Molec-
ular Devices Inc., Sunnyvale, USA).
Imaging and data processing
Imaging of mammalian cells was performed on a fluorescence
microscope DM4000B (Leica Microsystems Gmbh) fitted with a
Table 1. Comparison of the dynamin 2 disease-causing mutations tested.
Disease CMT CNM
Mutations G358R K562E R465W R522H S619L P627H
Affected domain Middle PH Middle PH PH PH
Localization to MT’s
1 ++ ----
MT dynamics
2 MT stability
not affected
MT stability not
affected
CME and clathrin-positive
structures
1
normal and
clustered
strongly decreased
and clustered
decreased and
enlarged
decreased and
enlarged
decreased and
enlarged
decreased and
enlarged
CME in patient cells
2 normal normal
Golgi maintenance
1,2 normal normal normal normal normal normal
Centrosome cohesion
1,2 normal normal normal normal normal normal
1ectopic expression,
2in patient fibroblasts.
doi:10.1371/journal.pone.0027498.t001
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with a confocal laser scanning microscope (SP2; Leica Micro-
systems Gmbh) on an upright DMRXA2 microscope using the
6361.4 oil immersion lens. Data processing was performed using
ImageJ (Rasband, W.S., ImageJ, U.S. National Institutes of
Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/,
1997–2009) or Adobe Photoshop CS2 (Adobe Systems Incorpo-
rated). The mask was generated using the Fiji program (http://
pacific.mpi-cbg.de/wiki/index.php/User:Schindelin).
Pull-down assays
Recombinant GST and GST-SH3 (BIN1) were expressed in the
Rosetta BL21 cell line. The recombinant proteins were purified
employing glutathione coupled beads (GE Healthcare). COS-1 cells
transiently transfected with WT or mutant human dynamin 2
constructs were solubilized in lysis buffer [20 mM HEPES-KOH
(pH 7.4), 100 mM NaCl, 1 mM MgCl2, 0.5% (v/v) Triton X-100,
1 mM EGTA, 1 mM DTT, 5% (v/v) glycerol with a protease
inhibitor cocktail (Roche)] for 1 h at 4uC. The soluble fraction that
was recovered following centrifugation at 20,000 x g for 30 min at
4uC was combined to glutathione beads coupled to GST or GST-
SH3 (BIN1) overnight. Unbound proteins wereremoved by washing
with lysis buffer. Bound proteins were eluted by addition of Laemli
buffer and were analyzed by SDS-PAGE followed by staining in
CoomassieBlueorweresubjected towesternblot analysisemploying
the R2680 anti-dynamin 2 antibody (IGBMC; [42]).
Supporting Information
Figure S1 CNM mutations impact on dynamin 29s
localization to microtubules. COS-1 cells transiently trans-
fected with the indicated constructs were treated with Brinkley
buffer and 1% (v/v) Triton X-100, followed by fixation in
parafomaldehyde and staining with anti-dynamin 2 and anti-b
tubulin specific antibodies. Dynamin 2 mutants (R522H, P627H)
do not localize to microtubules but decorate punctate structures
following MT enrichment.
(TIF)
Figure S2 Effect of dynamin mutants’ overexpression
on transferrin uptake. COS-1 cells expressing ectopic wild
type and mutant dynamin 2 constructs were incubated with
fluorescently labeled transferrin for 15 min and were subsequently
fixed and processed with anti-MYC antibodies for microscopic
observation. Representative images employed for quantification
experiments described in Figure 4.
(TIF)
Figure S3 Localization of dynamin 2 mutant constructs
to clathrin-positive structures following a vesicular
enrichment fixation. COS-1 cells were transiently transfected
with indicated dynamin 2 mutant constructs. Conditional
dynamin knock-out cells were left untreated (CKO) or were
treated with 4-hydroxytamoxifen for deletion of Dnm1 and Dnm2
(DKO). Cells were treated with 0.5% (v/v) Triton X-100, 2% (v/
v) paraformaldehyde for 2 min at 37uC followed by fixation in
paraformaldehyde and processing with anti-MYC specific anti-
bodies and anti-clathrin light chain (CLC) antibodies. Samples
were analyzed by confocal microscopy. A mask for the
colocalization was created employing the Fiji software is shown
(right panels). Note the presence of enlarged vesicles (arrows) in the
case of R522H and P627H mutant expressing cells.
(TIF)
Figure S4 CNM and CMT dynamin 2 mutations do not
impact on BIN1 (amphiphysin 2) interaction. Recruitment
of dynamin 2 constructs to BIN1-induced membrane tubules.
COS-1 cells were transiently transfected with vectors encoding
indicated dynamin 2 constructs and the GFP-BIN1 chimera. Cells
were fixed in paraformaldehyde followed by staining with anti-
MYC specific antibodies. Both CNM and CMT dynamin 2
mutants can be seen in association with BIN1 tubules.
(TIF)
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